<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413542</url>
  </required_header>
  <id_info>
    <org_study_id>HL079184</org_study_id>
    <nct_id>NCT01413542</nct_id>
    <nct_alias>NCT00139503</nct_alias>
  </id_info>
  <brief_title>Pharmacogenetics of Ace Inhibitor-Associated Angioedema</brief_title>
  <official_title>Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4
      inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people
      receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure
      medicine. Understanding how these drugs interact in healthy people will help us learn their
      potential effects in people who have diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test the hypothesis that DPPIV inhibition with sitagliptin potentiates the vasodilator
      response to substance P in the presence of ACE inhibition with enalaprilat and to BNP and
      GLP-1 even in the presence of ACE inhibition. The aim promises to provide important new data
      regarding the mechanism of action of DPPIV inhibitors and interactive effects of these two
      drug classes used in a growing population of diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).</measure>
    <time_frame>60 minutes post-placebo or sitagliptin (DPP4 inhibition) and over last 2 minutes of each 5 min infusion per peptide dose (30 min washout between peptides); sequence repeated with enalaprilat (ACE inhibition) or vehicle</time_frame>
    <description>Forearm blood flow (FBF) was measured by strain gauge plethysmography at the completion of each dose of intra-arterial peptide. A dose response curve was therefore constructed for each vasoactive peptide substrate. The effect of sitagliptin (DPP4 inhibition) vs. placebo and enalaprilat (ACE inhibition) vs. vehicle on the forearm blood flow response to each peptide could then be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Tissue Type Plasminogen Activator (tPA) Release</measure>
    <time_frame>Blood for analysis of tPA release was obtained 60 minutes after sitagliptin (DPP4 inhibition) vs. placebo and after each assessment of FBF (see primary outcome measure)</time_frame>
    <description>Following measurement of FBF, samples will be obtained to determine the effect of ACE inhibition and/or DPP4 inhibition on tPA release in response to bradykinin and substance P (SP) (group 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Effect of ACE and/or DPP4 Inhibition on Heart Rate Response to Substance P (SP)</measure>
    <time_frame>Heart rate was measured every 5 minutes throughout the study day (and thus during each dose of peptide infusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Treatment (ACE or DPP4 Inhibition, or Combined) on Norepinephrine (NE) Release (Arterial Venous Gradient) in Response to Substance P (SP)</measure>
    <time_frame>Blood for analysis of norepinephrine (NE) release was obtained 60 minutes after sitagliptin (DPP4 inhibition) vs. placebo and after each assessment of FBF (see primary outcome measure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion</measure>
    <time_frame>Blood for analysis of GLP-1 levels was obtained one hour after sitagliptin (DPP4 inhibition) vs. placebo administration and after each dose of GLP-1</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo then sitagliptin (DPP4 inhibition) group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then placebo group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then sitagliptin group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then comparator group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin (DPP4 inhibitor)</intervention_name>
    <description>Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions</description>
    <arm_group_label>Placebo then sitagliptin (DPP4 inhibition) group 1</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then placebo group 1</arm_group_label>
    <arm_group_label>Placebo then sitagliptin group 2</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then comparator group 2</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Substance P,</intervention_name>
    <description>Substance P intra-brachial artery (2,4,8 pmol/min)</description>
    <arm_group_label>Placebo then sitagliptin (DPP4 inhibition) group 1</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then placebo group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bradykinin</intervention_name>
    <description>bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)</description>
    <arm_group_label>Placebo then sitagliptin (DPP4 inhibition) group 1</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then placebo group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enalaprilat (ACE inhibitor)</intervention_name>
    <description>intra-brachial artery(0.33 Âµg/min per 100 mL forearm volume)</description>
    <arm_group_label>Placebo then sitagliptin (DPP4 inhibition) group 1</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then placebo group 1</arm_group_label>
    <other_name>vasotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-like peptide 1</intervention_name>
    <description>intra-brachial artery (0.45-3.60 pmol/min)</description>
    <arm_group_label>Placebo then sitagliptin group 2</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then comparator group 2</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brain natriuretic peptide</intervention_name>
    <description>Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)</description>
    <arm_group_label>Placebo then sitagliptin group 2</arm_group_label>
    <arm_group_label>Sitagliptin (DPP4 inhibition) then comparator group 2</arm_group_label>
    <other_name>nesiritide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 inclusive

          -  Men and women

          -  Black and White Americans

          -  BMI &lt;25

        For female subjects:

          -  Postmenopausal status for at least 1 year

          -  Status post surgical sterilization

          -  If childbearing potential, utilization of a barrier method of birth control and
             willingness to undergo blood B-hcg testing prior to drug treatment and on every study
             day

        Exclusion Criteria:

          -  Smoking

          -  Diabetes type 1 or 2, as defined by a fasting glucose of 126 mg/dl or greater or the
             use of anti-diabetic medication

          -  Hypertension as defined by an untreated seated SBP greater than 140 mmHg an untreated
             DBP greater than 90 mmHg or the use of antihypertensives

          -  History of reported or recorded hypoglycemia (plasma glucose less than 70 mg/dl)

          -  Pregnancy

          -  Breast-feeding

          -  Use of hormone replacement therapy

          -  The use of contraceptive therapy

          -  Use of any medication other than multivitamin

          -  Hematocrit &lt;35%

          -  Cardiovascular disease such as history of myocardial infarction, presence of angina
             pectoris, significant arrhythmia, congestive heart failure(LV hypertrophy acceptable),
             deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral
             valve stenosis, aortic stenosis or hypertrophic cardiomyopathy

          -  Asthma

          -  History of angioedema

          -  History of cough or other side effect during ACE inhibitor use

          -  Impaired renal function, as defined by an eGFR&lt;60ml/min/1.73M2

          -  Clinically significant gastrointestinal impairment that could interfere with drug
             absorption

          -  Impaired hepatic function (aspartate amino transaminase[AST] and/or alanine amino
             transferase [ALT]&gt;2 x upper limit of normal range

          -  History of alcohol or drug abuse

          -  Treatment with any investigational drug in the 1 month preceding the study

          -  Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

          -  Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return to follow-up visits, and the unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University- General Clinic Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <results_first_submitted>November 7, 2014</results_first_submitted>
  <results_first_submitted_qc>October 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2015</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Chair of Dept of Medicine</investigator_title>
  </responsible_party>
  <keyword>DPPIV inhibitors</keyword>
  <keyword>ACE inhibitors</keyword>
  <keyword>Bradykinin</keyword>
  <keyword>glucagon-like peptide (GLP-1)</keyword>
  <keyword>BNP</keyword>
  <keyword>diabetes</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
    <mesh_term>Kininogens</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>44 participants were enrolled in this study (23 in Group 1 and 21 in Group 2) and completed screening procedures. Twelve of 23 participants met inclusion and exclusion criteria and completed all study-related procedures in Group 1. Seventeen of 21 participants met inclusion/exclusion criteria and completed all study-related procedures in Group 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Sitagliptin (DPP4 Inhibibition)=Group 1</title>
          <description>Participants first received Placebo then Sitagliptin 200 mg by mouth one time on each of two study days. Two weeks separated each study day. Each study day examined the effect of vehicle and enalaprilat on the forearm blood flow and tPA responses to bradykinin and substance P.</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin (DPP4 Inhibition) Then Placebo=Group 1</title>
          <description>Participants first received Sitagliptin 200 mg then Placebo by mouth one time on each of two study days. Two weeks separated each study day. Each study day examined the effect of vehicle and enalaprilat on the forearm blood flow and tPA responses to bradykinin and substance P.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Sitagliptin (DPP4 Inhibition)=Group 2</title>
          <description>Participants first received Placebo then Sitagliptin 200 mg by mouth one time on each of two study days. Two weeks separated each study day. Each study day examined the forearm blood flow and tPA responses to brain natriuretic peptide (BNP) and glucagon-like receptor 1 (GLP-1).</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin (DPP4 Inhibition) Then Placebo = Group 2</title>
          <description>Participants first received Sitagliptin 200 mg then Placebo by mouth one time on each of two study days. Two weeks separated each study day. Each study day examined the forearm blood flow and tPA responses to brain natriuretic peptide (BNP) and glucagon-like receptor 1 (GLP-1).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This population represents the 29 participants (12 in Group 1; 17 in Group 2) who passed screening and completed at least one study arm. 1 subject did not complete the 2nd arm in Group 1. 4 subjects did not complete the second arm in Group 2. Results and baseline characteristics are presented inclusive of these patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Participants were randomized to sitagliptin 200 mg vs. placebo on each of two study days. On each study day, the effects of vehicle and enalaprilat on forearm blood flow and tPA responses to bradykinin and substance P were studied.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Participants were randomized to sitagliptin 200 mg vs. placebo on each of two study days. On each study day, the effect of brain natriuretic peptide and glucagon like receptor-1 (GLP-1) on forearm blood flow and tPA release was studied.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="12.0"/>
                    <measurement group_id="B2" value="35.4" spread="10.0"/>
                    <measurement group_id="B3" value="36.5" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).</title>
        <description>Forearm blood flow (FBF) was measured by strain gauge plethysmography at the completion of each dose of intra-arterial peptide. A dose response curve was therefore constructed for each vasoactive peptide substrate. The effect of sitagliptin (DPP4 inhibition) vs. placebo and enalaprilat (ACE inhibition) vs. vehicle on the forearm blood flow response to each peptide could then be determined.</description>
        <time_frame>60 minutes post-placebo or sitagliptin (DPP4 inhibition) and over last 2 minutes of each 5 min infusion per peptide dose (30 min washout between peptides); sequence repeated with enalaprilat (ACE inhibition) or vehicle</time_frame>
        <population>In Group 1: Peptide 1=Max dose Bradykinin; Peptide 2=Substance P (SP) In Group 2: Peptide 1=GLP-1; Peptide 2=BNP (FBF expressed as percent change for both peptides) ACE inhibition=enalaprilat DPP4 inhibition=sitagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants were randomized to sitagliptin 200 mg (DPP4 inhibitor) vs. placebo on each of two study days. On each study day, the effects of vehicle and enalaprilat (ACE inhibitor) on forearm blood flow and tPA responses to bradykinin (peptide 1) and substance P (SP) (peptide 2) were studied.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants were randomized to sitagliptin 200 mg (DPP4 inhibitor) vs. placebo on each of two study days. On each study day, the effect of study drug on FBF response to glucagon like peptide-1 (peptide 1) and brain natriuretic peptide (peptide 2) was studied.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).</title>
          <description>Forearm blood flow (FBF) was measured by strain gauge plethysmography at the completion of each dose of intra-arterial peptide. A dose response curve was therefore constructed for each vasoactive peptide substrate. The effect of sitagliptin (DPP4 inhibition) vs. placebo and enalaprilat (ACE inhibition) vs. vehicle on the forearm blood flow response to each peptide could then be determined.</description>
          <population>In Group 1: Peptide 1=Max dose Bradykinin; Peptide 2=Substance P (SP) In Group 2: Peptide 1=GLP-1; Peptide 2=BNP (FBF expressed as percent change for both peptides) ACE inhibition=enalaprilat DPP4 inhibition=sitagliptin</population>
          <units>estimate of difference(ml/min/100ml FBF)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effect ACE inhibition on FBF response to Peptide 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 1 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect DPP4 inhibition on FBF Response to Peptide1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-2.4" upper_limit="2.7"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-11.6" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect ACE/DPP4 inhibit on FBF response Peptide 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="3.3" upper_limit="8.4"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 1 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect DPP4/ACEinhib vs. ACEinhib (FBF to Pep1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-3.1" upper_limit="1.9"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 1 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect DPP4/ACEinhib vs. DPP4inhib (FBF to Pep1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="3.2" upper_limit="8.2"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 1 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect ACE inhibition on FBF response to Peptide 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-0.3" upper_limit="2.0"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 2 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect DPP4 inhibition on FBF response to Peptide2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-3.2" lower_limit="-37.4" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect ACE/DPP4 inhibition on Peptide 2 FBF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-0.6" upper_limit="1.7"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 2 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect DPP4/ACEinhib vs. ACEinhib (FBF to Pep2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.4" upper_limit="0.9"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 2 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect DPP4/ACEinhib vs. DPP4inhib (FBF to Pep2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.8" upper_limit="1.6"/>
                    <measurement group_id="O2" value="NA">effect of ace inhibition not studied in this group as peptide 2 is not a substrate of ace</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1: The effect of treatment (placebo, ACE or DPP4 inhibitor, or the combination) on vasodilator response to peptide, measured as forearm blood flow was determined.
Group 2: The effect of treatment (placebo, DPP4 inhibitor) on vasodilator response to peptide, measured as percent change in forearm blood flow was determined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Effect of ACE inhibition on FBF response to bradykinin (p&lt;0.001). Other comparisons: Effect of DPP4 inhibition on FBF response to bradykinin (p=0.89); Effect of ACE (p=0.16), DPP4 (p=0.82), or combined inhibition (p=0.35) on FBF response to sub P.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Effect of DPP4 inhibition on vasodilator response to GLP-1 (p=0.14) or BNP (p=0.85).
p&lt;0.05 threshold for statistical significance.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Tissue Type Plasminogen Activator (tPA) Release</title>
        <description>Following measurement of FBF, samples will be obtained to determine the effect of ACE inhibition and/or DPP4 inhibition on tPA release in response to bradykinin and substance P (SP) (group 1)</description>
        <time_frame>Blood for analysis of tPA release was obtained 60 minutes after sitagliptin (DPP4 inhibition) vs. placebo and after each assessment of FBF (see primary outcome measure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Males)</title>
            <description>The effect of ACE inhibition and/or DPP4 inhibition on tPA release in response to bradykinin and substance P (SP) was evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Group 1 (Females)</title>
            <description>The effect of ACE inhibition and/or DPP4 inhibition on tPA release in response to bradykinin and substance P (SP) was evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Tissue Type Plasminogen Activator (tPA) Release</title>
          <description>Following measurement of FBF, samples will be obtained to determine the effect of ACE inhibition and/or DPP4 inhibition on tPA release in response to bradykinin and substance P (SP) (group 1)</description>
          <units>estimate of difference (ng/min/100mL)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effect ACE inhibition on bradykinin tPA release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.6" lower_limit="78.9" upper_limit="158.4"/>
                    <measurement group_id="O2" value="145.5" lower_limit="107.0" upper_limit="184.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect of DPP4 inhibition on bradykinintPA release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-38.6" upper_limit="41.8"/>
                    <measurement group_id="O2" value="12.9" lower_limit="-26.5" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect of ACE/DPP4 inhibitio on bradykinin tPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="50.8" upper_limit="131.0"/>
                    <measurement group_id="O2" value="132.1" lower_limit="93.8" upper_limit="170.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>effect ace/dpp4 vs. aceinhibi on bradykinin tpa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" lower_limit="-68.2" upper_limit="12.6"/>
                    <measurement group_id="O2" value="-13.4" lower_limit="-52.1" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>effect ace/dpp4 vs. dpp4inhib on bradykinin tpa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="48.5" upper_limit="130.1"/>
                    <measurement group_id="O2" value="119.3" lower_limit="80.2" upper_limit="158.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect of ACE inhibition on SP tPA release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" lower_limit="-41.8" upper_limit="11.3"/>
                    <measurement group_id="O2" value="43.9" lower_limit="19.8" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect of DPP4 inhibition on SP tPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" lower_limit="-52.4" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-29.0" lower_limit="-53.4" upper_limit="-4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effect of ACE+DPP4 inhibition on SP tPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-25.8" upper_limit="27.3"/>
                    <measurement group_id="O2" value="3.8" lower_limit="-20.5" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>effect ace/dpp4 vs. aceinhibi on SP tpa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="-10.5" upper_limit="42.6"/>
                    <measurement group_id="O2" value="-40.1" lower_limit="-64.5" upper_limit="-15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>effect ace/dpp4 vs. dpp4inhibi on SP tpa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="0.0" upper_limit="53.1"/>
                    <measurement group_id="O2" value="32.8" lower_limit="8.6" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>Effect of DPP4 inhibition on tPA release during sub P in women (p=0.02 vs. placebo).Effect of ACE inhibition on tPA release during sub P in women (p&lt;0.001); effect of DPP4 inhibition on tPA release during sub P and (p=0.001 vs. ACE inhibition alone).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>p&lt;0.05 threshold for statistical significance</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Effect of ACE and/or DPP4 Inhibition on Heart Rate Response to Substance P (SP)</title>
        <time_frame>Heart rate was measured every 5 minutes throughout the study day (and thus during each dose of peptide infusion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>The effect of ACE and/or DPP4 inhibition on change in heart rate in response to substance P (SP) was evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Effect of ACE and/or DPP4 Inhibition on Heart Rate Response to Substance P (SP)</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Pulse after SP during Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Pulse after SP w/ACE inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Pulse after SP w/DPP4inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse change after SP w/ACE+DPP4inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>Effect of combined ACE and DPP4 inhibition on change in heart rate in response to max dose substance P (p=0.011 vs placebo; ).</p_value_desc>
            <method>Wilcoxon signed rank</method>
            <method_desc>p&lt;0.05 threshold for statistical significance.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Treatment (ACE or DPP4 Inhibition, or Combined) on Norepinephrine (NE) Release (Arterial Venous Gradient) in Response to Substance P (SP)</title>
        <time_frame>Blood for analysis of norepinephrine (NE) release was obtained 60 minutes after sitagliptin (DPP4 inhibition) vs. placebo and after each assessment of FBF (see primary outcome measure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants were randomized to sitagliptin 200 mg (DPP4 inhibitor) vs. placebo on each of two study days. On each study day, the effects of vehicle and enalaprilat (ACE inhibitor) on forearm blood flow and tPA responses to bradykinin (peptide 1) and substance P (SP) (peptide 2) were studied.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Treatment (ACE or DPP4 Inhibition, or Combined) on Norepinephrine (NE) Release (Arterial Venous Gradient) in Response to Substance P (SP)</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change NE AV Gradient with SP after placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.18" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change NE AV Gradient with SP after ACEinhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.18" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change NE AV Gradient with SP after DPP4inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.27" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change NE AV with SP after ACE+DPPinhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.45" spread="31.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Effect of combined DPP4 and ACE inhibition on the change in the norepinephrine AV gradient during substance P as compared to treatment with placebo.</p_value_desc>
            <method>Wilcoxon signed rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Effect of combined DPP4 and ACE inhibition on the change in the norepinephrine AV gradient during substance P as compared to treatment with ACE inhibition alone (p=0.007).</p_value_desc>
            <method>Wilcoxon signed rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion</title>
        <time_frame>Blood for analysis of GLP-1 levels was obtained one hour after sitagliptin (DPP4 inhibition) vs. placebo administration and after each dose of GLP-1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>The effect of treatment (placebo vs. DPP4 inhibition) on venous GLP-1 levels during intra-arterial GLP-1 infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Venous GLP-1 levels 1 hour after placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous GLP-1 Levels after Max Dose GLP-1 (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.44" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous GLP-1 levels 1 hour after DPP4 inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous GLP-1 levels Max Dose GLP-1 (DPP4inhibiton)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.63" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Effect of intra-arterial GLP-1 on venous GLP-1 concentrations during placebo (p=0.01).</p_value_desc>
            <method>wilxocon signed rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Effect of intra-arterial GLP-1 on venous GLP-1 concentrations during sitagliptin (p=0.01).</p_value_desc>
            <method>Wilcoxon signed rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>Effect of DPP4 inhibition on venous GLP-1 levels at high dose of intra-arterial GLP-1 (p=0.04 vs. placebo).</p_value_desc>
            <method>Wilcoxon signed rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>1 Subject (Group 1) did not complete sitagliptin arm due to inability to establish arterial access.
1 Subject (Group 2) did not complete placebo arm because the Investigator withdrew them after Serious Adverse Event.
3 Subjects (Group 2) did not complete the sitagliptin arm due to inability to establish arterial access during the sitagliptin arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (Placebo Arm)</title>
          <description>Participants were randomized to sitagliptin 200 mg vs. placebo on each of two study days. On each study day, the effects of vehicle and enalaprilat on forearm blood flow and tPA responses to bradykinin and substance P were studied.</description>
        </group>
        <group group_id="E2">
          <title>Group 1 (Sitagliptin Arm)</title>
          <description>Participants were randomized to sitagliptin 200 mg vs. placebo on each of two study days. On each study day, the effects of vehicle and enalaprilat on forearm blood flow and tPA responses to bradykinin and substance P were studied.</description>
        </group>
        <group group_id="E3">
          <title>Group 2 (Placebo Arm)</title>
          <description>Participants were randomized to sitagliptin 200 mg vs. placebo on each of two study days. On each study day, the effect of brain natriuretic peptide and glucagon like receptor-1 (GLP-1) on forearm blood flow and tPA release was studied.</description>
        </group>
        <group group_id="E4">
          <title>Group 2 (Sitagliptin Arm)</title>
          <description>Participants were randomized to sitagliptin 200 mg vs. placebo on each of two study days. On each study day, the effect of brain natriuretic peptide and glucagon like receptor-1 (GLP-1) on forearm blood flow and tPA release was studied.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostasis with Syncopal Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling of instrumented arm</sub_title>
                <description>One woman experienced angioedema of the instrumented forearm after infusion of bradykinin and substance P on the sitagliptin treatment day.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Transient Lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropraxia in the instrumented arm</sub_title>
                <description>Resolved over 2 weeks without therapy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>Within 2 weeks of completion of first study day.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nancy J. Brown</name_or_title>
      <organization>Department of Medicine Vanderbilt University Medical Center</organization>
      <phone>615-343-8701</phone>
      <email>nancy.j.brown@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

